The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1750 participants.

Also called NCT05374291

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,750 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05374291
  • EudraCT 2021-005446-15
  • EU CT 2023-508389-13-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Belgium, Germany, Netherlands, Singapore, Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05374291. Randomized; double masking; primary purpose prevention. Start 2022-11-08 (actual); primary completion 2027-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
Condition
Kidney Disease, Chronic
Condition
Renal Transplant Failure
Condition
Heart Failure
Condition
Kidney Failure
Condition
Death
Intervention (Drug)
Dapagliflozin 10 mg/day (oral)
Intervention (Drug)
Placebo
Lead sponsor
University Medical Center Groningen (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
Dutch Kidney Foundation (class: other)

Record details

Record id
cardio:ct-nct05374291
Content hash
46775ac8d7bbb8a64c18ec74e9855d6184e1ef26570512edb79a09114d476f0a